PARP1 and gastric cancer: It targets the 3’-untranslated region of PARP1 mRNA by recruiting YTHDF1, resulting in enhanced stability of PARP1 and consequently facilitating the development of oxaliplatin resistance in gastric cancer cells.[30] Cisplatin is another frequently utilized drug in the treatment of gastric cancer.